The estimated Net Worth of Investment Group Lp Senator is at least $2.04 Million dollars as of 19 April 2012. Investment Senator owns over 91,000 units of Idera Pharmaceuticals stock worth over $1,171,621 and over the last 13 years Investment sold IDRA stock worth over $868,981.
Investment has made over 5 trades of the Idera Pharmaceuticals stock since 2012, according to the Form 4 filled with the SEC. Most recently Investment sold 91,000 units of IDRA stock worth $171,080 on 19 April 2012.
The largest trade Investment's ever made was selling 120,000 units of Idera Pharmaceuticals stock on 17 April 2012 worth over $255,600. On average, Investment trades about 89,101 units every 4 days since 2012. As of 19 April 2012 Investment still owns at least 2,724,700 units of Idera Pharmaceuticals stock.
You can see the complete history of Investment Senator stock trades at the bottom of the page.
Investment's mailing address filed with the SEC is 510 MADISON AVENUE, 28TH FLOOR, NEW YORK, NY, 10022.
Over the last 17 years, insiders at Idera Pharmaceuticals have traded over $20,746,904 worth of Idera Pharmaceuticals stock and bought 38,459,430 units worth $53,771,070 . The most active insiders traders include Bros. Advisors Lp14159, L.P..., Bros. Advisors Lp Baker Bro... und Invest Corp Pillar Pharmace.... On average, Idera Pharmaceuticals executives and independent directors trade stock every 43 days with the average trade being worth of $309,429. The most recent stock trade was executed by John J. Kirby on 17 December 2021, trading 10,000 units of IDRA stock currently worth $6,200.
Harnessing the approach of the earliest researchers in immunotherapy and the company's vast experience in developing proprietary immunology platforms, Idera's development program is focused on priming the immune system to play a more powerful role in fighting cancer, ultimately increasing the number of people who can benefit from immunotherapy. Idera also continues to focus on the acquisition, development, and ultimate commercialization of drug candidates for both oncology and rare disease indications characterized by small, well-defined patient populations with serious unmet needs.
Idera Pharmaceuticals executives and other stock owners filed with the SEC include: